Comparison of the virulence of Streptococcus pneumoniae in ICR mouse stocks of three different origins
- 122 Downloads
Streptococcus pneumoniae causes many people to suffer from pneumonia, septicemia, and other diseases worldwide. To identify the difference in susceptibility of and treatment efficacy against S. pneumoniae in three ICR mouse stocks (Korl:ICR, A:ICR, and B:ICR) with different origins, mice were infected with 2 × 106, 2 × 107, and 2 × 108 CFU of S. pneumoniae D39 intratracheally. The survival of mice was observed until three weeks after the infection. The three stocks of mice showed no significant survival rate difference at 2 × 106 and 2 × 107 CFU. However, the lung and spleen weight in the A:ICR stock was significantly different from that in the other two stocks, whereas the liver weight in B:ICR stock was significantly lower than that in the other two stocks. Interestingly, no significant CFU difference in the organs was observed between the ICR stocks. The level of interferon gamma inducible protein 10 in Korl:ICR was significantly lower than that in the other two stocks. The level of granulocyte colony stimulating factor in B:ICR was significantly lower than in the other two stocks. However, tumor-necrosis factor-alpha and interleukin-6 levels showed no significant difference between the ICR stocks. In the vancomycin efficacy test after the S. pneumoniae infection, both the single-dose and double-dose vancomycin-treated groups showed a significantly better survival rate than the control group. There was no significant survival difference between the three stocks. These data showed that Korl:ICR, A:ICR, and B:ICR have no susceptibility difference to the S. pneumoniae D39 serotype 2.
KeywordsStreptococcus pneumonia D39 Vancomycin Survival rate
Colony forming unit
Enzyme linked immunosorbent assay
Granulocyte colony stimulating factor
Interferon gamma inducible protein 10
Phosphate buffered saline
- S. pneumoniae
IL-17 producing T-helper cell
- TNF- α
Tumor necrosis factor- α
Streptococcus pneumonia is a gram-positive pathogen that affects humans [1, 2]. The treatment for infection with S. pneumoniae requires taking antibiotics. This pathogen causes several infectious diseases such as pneumonia, meningitis , and acute otitis media  and acute sinusitis .
The occurrence of pneumococcal and acute respiratory infections is decreasing but is still considerably high in children under the age of 5 and in elders with weak immunity, in developing countries. Approximately 20–25% of all mortalities in children are identified to be a bacterial pneumonia caused by S. pneumoniae [4, 6]. The pathogen normally occupies the nasopharynx. The use of antibiotics in the treatment of the disease is impeded by the increase in the resistance of pneumonia strains to the therapy. Additionally, antibiotics cannot decrease the mortality rate of disease in the first 3 days of treatment, which emphasizes the need for deeper knowledge on the pathogenesis of pneumococcal disease . Despite the high mortality worldwide, the host-pathogen interaction during S. pneumoniae infection is poorly understood and in depth knowledge is required .
The significance of animal models is well known especially in studying infectious diseases, as well as treatment efficacies. Animal models allow investigators to simulate various immune states and adjust the severity of infection in vivo, which allows in depth pharmacokinetic and pharmacodynamic measurements . ICR mice are an outbred which Swiss in origin those are used in various field of research study. Multiple suppliers produce their own commercial ICR stocks which lead to characteristic varieties . This study was performed to investigate the difference in the susceptibility of and treatment efficacy against S. pneumoniae serotype 2 D39 in differently originated ICR outbred mice.
Materials and methods
Seven-week-old male ICR mice were obtained from three difference sources. Korl:ICR was obtained from Koatech (Gyeonggi-do, Korea). A:ICR and B:ICR mice were purchased through Orient Bio Inc.(Gyeonggi-do, Korea) and Japan SLC (Shizuoka, Japan), respectively. Mice were acclimatized for a week at the pathogen-free animal facility at the College of Veterinary Medicine, Konkuk University (Seoul, Korea). Five mice were bred per sterilized polycarbonate cage and allowed 24-h access to sterilized food and water, and provided with sterilized wooden bedding. The facility was maintained with 12-h light/dark cycle and the temperature was maintained at 22 ± 2 °C and 50 ± 10% humidity. The surviving animals after the examination were euthanized in a CO2 gas chamber. All the procedures were approved by the Institutional Animal Care and Use Committee.
Streptococcus pneumoniae D39 preparation
S. pneumoniae D39 serotype 2 was obtained from the Korean Centers for Disease Control and Prevention (KCDC, Osong, Korea) and stored at − 70 °C. The bacterial cells were placed at room temperature on ice until complete melting and cultured on a 5% sheep blood agar plate at 37 °C with 5% CO2 supplement for 16 h. Bacteria were harvested and re-suspended in sterilized phosphate buffered saline (PBS) to an optical density value of 0.3. Then the bacteria-PBS stock was transferred to brain-heart infusion broth (Merck, Darmstadt, Germany) and incubated at 37 °C with 5% CO2 for 6 h. The bacterial solution was centrifuged at 4500 rpm for 5 min. The concentration of bacteria was measured by optical density absorbance value at 600 nm using spectrometer. Colony forming units (CFU) per μL were counted using sheep blood agar plate with serially diluted bacterial suspension.
S. pneumoniae D39 stocks were prepared at 2 × 106, 2 × 107, and 2 × 108 CFU. Mice were intraperitoneally anesthetized with a mixture of Ketamine (Yuhan chemical Inc., Seoul, Korea) and Rumpun (Bayer Korea, Seoul, Korea). A total of 30 μL of S. pneumoniae suspension (2 × 106, 2 × 107, and 2 × 108 CFU) was injected via exposed tracheae using a 31-gauge needle, via intratracheal injection. The skin incision was closed with suture materials. The clinical signs and death of ICR mice (n = 10 per group) were observed twice daily and body weight was measured once a day for 21 days after the injection of bacteria.
Three ICR stocks (n = 10 per group) were injected with 30 μL of 2 × 106 CFU S. pneumoniae D39 intra-tracheally after anesthetization. The mice underwent autopsy at 48 h after the infection. Blood samples were collected via caudal vena cava and stored at − 4 °C overnight for serum separation. Liver, spleen, and lung were harvested and weighed in sterile conditions. Each organ was divided into two at each lobe; one half of the organ was immersed into liquid nitrogen and stored in a deep freezer (− 70 °C) and the other half was homogenized with sterile PBS for CFU analysis immediately after the extraction.
Vancomycin efficacy test
Each ICR stock was injected with 30 μL of 2 × 106 S. pneumoniae D39 intratracheally. The vancomycin single-dose treatment group (n = 6) of each ICR stock was treated with 30 mg/kg of vancomycin at 18 h after infection. Vancomycin double-dose treatment group (n = 6) was treated with 30 mg/kg of vancomycin at both 18 h and 42 h after infection. The control group (n = 10) was treated with PBS at both 18 h and 42 h after infection. The clinical signs and death of ICR mice were observed twice daily and body weight was measured once a day for 21 days after the injection of bacteria.
The liver, spleen, and lung tissues were weighed (30 mg) and homogenized with four times the titer of sterile PBS and subjected to serial dilution. The diluted homogenates were spread on 5% sheep blood agar plate and incubated for 24 h at 37 °C with 5% CO2. The S. pneumoniae colonies were then counted.
Enzyme-linked immunosorbent assay (ELISA)
Blood serum was separated by centrifugation from the collected blood samples. The levels of the cytokines tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), interferon gamma inducible protein 10 (IP-10), and granulocyte colony stimulating factor (G-CSF) were measured using the Duoset ELISA kit (R&D systems, Minneapolis, MN) by following the manufacturers’ instruction. Blood serum was 1:5 in diluent buffer. The cytokine levels were analyzed using corresponding standard curve, and measurement of absorbance at 450 nm and 570 nm.
Analyses of the data were performed through Prism 5 (Graphpad Software Inc.). Quantitative data are expressed as the mean values with standard deviation. Log-rank test was used to determine the survival difference and the significant difference between the groups was analyzed by the two-tailed Student’s t-test. The value of P < 0.05 was considered to be statistically significant.
Survival rate examination in the different mouse stocks
Pathogenicity examination in the different mouse stocks
Effect of vancomycin treatment in the different mouse stocks
S. pneumoniae infection is fatal in children living in developing countries  and the entire population is at risk of suffering from pneumococcus infection throughout their life time . Many studies use murine models to investigate the pneumococcal bacteria that cause pneumonia. This study was identified the susceptibility and treatment efficacy differences against S. pneumoniae serotype 2 D39 between Korl:ICR, A:ICR, and B:ICR sources.
A total of 2 × 106, 2 × 107, and 2 × 108 CFU doses of S. pneumoniae were inoculated via intratracheal injection. The onset of death started 1 day after the infection with 2 × 107 and 2 × 108 CFU and from day 2 with 2 × 106 CFU. The numbers of surviving mice at 21 days after infection with the CFU doses 2 × 106, 2 × 107 and 2 × 108 were 4, 2, and 1, respectively. As shown in Fig. 1, the higher CFU value showed more rapid and vigorous death. Upon infection with 2 × 108 CFU, the B:ICR mice showed a significantly higher death rate compared to the Korl:ICR and A:ICR stocks. In the other study, S. pneumoniae infection with 2 × 106 CFU, also showed no significant susceptibility difference between C3H/HeN, C57BL/6, and ICR .
The A:ICR stock showed a significantly higher lung weight and lower spleen weight compared to the Korl:ICR and B:ICR mice (P < 0.05). However, the liver weight was significantly lower in the B:ICR mice. Usually, the enlargement of spleen caused by pathogen-induced hyperplasia  can be the hallmark of severity of a disease and the lung weight considerably increases in the case of severe pneumonia . However, CFU analysis revealed no significant bacterial level differences in the spleen, lung, and liver between the three ICR stocks.
Cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) are found at high concentration upon tissue injury or bacteria-induced organ damage , and has a role in bacterial clearance in pulmonary infection [15, 16]. In addition, TNF-α reduced the thymocyte apoptosis against S. pneumonia infection . When BALB/c and C57BL/6 mice were infected with the S. pneumoniae serotype 3 WU2, spleen cytokine levels showed no alteration whereas infection with the S. pneumoniae serotype 14 DW14 in the same mice strains showed alteration of cytokine levels . The pro-inflammatory cytokine IP-10 level was elevated by S. pneumoniae and Neisseria meningitides . In 2 × 108 CFU S. pneumoniae infection, survival rate of B:ICR was also significantly lower than the other two stocks (Fig. 1c). G-CSF assists neutrophils to be released into blood from bone marrow  and mice with deficient G-CSF receptor were highly sensitive to fungal and bacterial infection . In case of mice infected with 2 × 106 CFU of S. pneumoniae, high level of serum G-CSF after 2 days of infection in Korl:ICR and A:ICR mice was closely associated with an increase of survival rate (Figs. 1a and 3d). These results are similar to previous reports that G-CSF pretreatment in mice and rats increased the survival rate in S. pneumoniae infection [22, 23]. TNF-α and IL-6 levels were not significantly different between the three ICR stocks, while Korl:ICR showed a significantly lower IP-10 level than the other two ICR stocks. G-CSF level in B:ICR was significantly lower than the other two stocks.
Vancomycin is a glycopeptide antibiotic that inhibits gram-positive bacteria, and leads to decrease in IL-17-producing T-helper cells (Th17), which are potent inflammatory activators . A vancomycin single-dose of 30 mg/kg and double-dose treatment after bacterial injection significantly increased the survival rate compared to that in the control group in all the ICR stocks. However, only the A:ICR stock showed a significantly better survival rate between the single-dose and double-dose vancomycin treatments. The A:ICR and B:ICR stocks treated with single-dose vancomycin showed 100% mortality; however, Korl:ICR showed 70% mortality. Thirty-three percent survived in Korl:ICR but no significant survival rate difference between the stocks was observed. The double-dose vancomycin treatment showed 80, 50, and 70% survival rate in Korl:ICR, A:ICR, and B:ICR, respectively. We found that the Korl:ICR stock was more sensitive to the antibiotic than the other ICR stocks. Repeated antibiotic treatment enhanced the survival rate of the three different stocks. Further study is needed to increase the survival rate beyond that obtained in the current study. Based on our results, due to the characteristics of the outbred ICR along with their different origins, the relative weight of the organs and the cytokine levels may vary, but the severity of infection caused by S. pneumoniae serotype 2 D39 was not significantly affected, except at high dose of bacterial load. Moreover, the repeated treatment with antibiotics increased the survival rate. Taken together, the Korl:ICR, A:ICR and B:ICR stocks have no difference in susceptibility to the S. pneumoniae D39 serotype 2 and this response profile may help other researchers searching for an ICR animal model in the future.
Three ICR mice stocks (Korl:ICR, A:ICR, and B:ICR) of mice showed no significant survival rate difference when mice were infected with at 2 × 106 and 2 × 107 CFU. And TNF-α and IL-6 levels showed no significant difference between the ICR stocks. However, Korl:ICR mice showed a significantly lower IP-10 level while B:ICR mice showed a significantly lower G-CSF level than the other two stocks. Our results indicate that there is no susceptibility difference to S. pneumonia D39 serotype 2 upon three different ICR stocks.
This project was supported by a grant of NLAR (National Laboratory Animal Resources) from Ministry of Food and Drug Safety in 2018.
Availability of data and materials
All data produced or analyzed during the current investigation are available from the corresponding author on reasonable request.
JYK, HWK, HKL and SMS performed experiments. JYK, HWK and CYK analyzed results. JYK and CYK prepared the Figures. CYK designed the research. JYK and CYK wrote the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
- 10.Levine OS, O'Brien KL, Knoll M, Adegbola RA, Black S, Cherian T, Dagan R, Goldblatt D, Grange A, Greenwood B, Hennessy T, Klugman KP, Madhi SA, Mulholland K, Nohynek H, Santosham M, Saha SK, Scott JA, Sow S, Whitney CG, Cutts F. Pneumococcal vaccination in developing countries. Lancet. 2006;367(9526):1880–2.CrossRefGoogle Scholar
- 22.Brandt CT, Lundgren JD, Lund SP, Frimodt-Møller N, Christensen T, Benfield T, Espersen F, Hougaard DM, Østergaard C. Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects rats from fatal outcome and brain damage during Streptococcus pneumoniae meningitis. Infect Immun. 2004;72(8):4647–53.CrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.